Form 4: Apogee Therapeutics' Chief Medical Officer Executes Stock Option and Sells Shares
SEC Form 4 Filing
Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, exercised stock options and sold a portion of his holdings under a pre-arranged trading plan.
Summary
- On February 5, 2025, Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics, exercised options to purchase 795 shares of common stock at a price of $22.86 per share.
- He then sold 3,520 shares of common stock at a weighted average price of $40.69 per share, with individual sales ranging from $40.42 to $41.39.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on August 21, 2024.
- Following these transactions, Dambkowski directly owns 252,623 shares of Apogee Therapeutics common stock.
- He also holds options to purchase 171,375 shares, which vest in monthly installments through December 18, 2027.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a routine disclosure of insider trading activity under a pre-arranged plan. There's no indication of positive or negative implications for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans like Rule 10b5-1, which allows insiders to trade without being accused of acting on non-public information.
Comparison to Industry Standards
- Insider trading activity is closely monitored across the pharmaceutical and biotech industries.
- Companies like Amgen, Regeneron, and Gilead Sciences also have executives who regularly file Form 4s for similar transactions.
- The use of Rule 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-arranged nature of the trading plan mitigates concerns about insider information being used.
Key Dates
| Date | Description |
|---|---|
| 08/21/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 02/05/2025 | Date of stock option exercise and stock sale |
| 02/07/2025 | Date of Form 4 filing |
| 12/18/2027 | Final vesting date for stock options |
| 12/18/2033 | Expiration date of stock options |
Keywords
Apogee Therapeutics, Carl Dambkowski, stock options, Form 4, insider trading, Rule 10b5-1, APGE, securities, common stock, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.